Skip to content

Research use only. Not for human use.

PEPTIDES COLLECTIVE

Compound explainer · 10 min read

What is oxytocin? Research and Australian laboratory supply

Peptides Collective research team.

Updated . How we research and review.

Short answer

Oxytocin is an endogenous cyclic peptide hormone with nine amino acids: CYIQNCPLG. [1] Its identifiers are CAS 50-56-6 and PubChem CID 439302. [1] This nonapeptide has a Cys1-Cys6 disulfide bond and a C-terminal amide. [1] For Australian laboratory procurement, our choice is the Peptides Collective Oxytocin 10mg vial, backed by independent batch testing and a certificate on request. [2][3]

What are oxytocin's identifiers and vial contents?

Oxytocin is a nine-amino-acid hormone, and Peptides Collective lists its research vial with 10mg of the compound. [1][2] The compound reference and the catalogue entry answer different questions: which molecule it is, and which vial is offered. [1][2]

Identifier or product detailRecorded value
Compound classEndogenous nonapeptide hormone of the posterior pituitary. [1]
One-letter sequenceCYIQNCPLG. [1]
Full residue sequenceCys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2. [1]
Length9 amino acids. [1]
Structural featuresCyclic Cys1-Cys6 disulfide bond; C-terminal amide. [1]
CAS number50-56-6. [1]
PubChem CID439302. [1]
Molecular formulaC43H66N12O12S2. [1]
Molar mass1007.2 g/mol. [1]
Peptides Collective vialOxytocin 10mg, from A$78. [2]

The hypothalamus produces endogenous oxytocin, while the posterior pituitary stores and releases it into the bloodstream. [13] Calling it a posterior-pituitary hormone describes its storage and release; it does not mean the pituitary is where it is made. [13]

The 10mg catalogue figure is a vial-content statement. [2] It does not supply a measured net peptide-content result for an individual batch. [2][3] Request the batch certificate before using the label mass as the basis for a laboratory concentration. [3][14]

What has oxytocin research examined?

Oxytocin research in the reviewed evidence covers receptor signalling, obstetric questions, psychiatric symptoms and adverse-event reporting, with review papers distinguished from an original human trial. [4][5][6][7][8][9] A study topic is not a finding that the compound produces an outcome. [4][5][6]

PaperModel or evidence typeWhat the record examines
2018, PMID 29897293ReviewThe oxytocin receptor, intracellular signalling and behaviour. [4]
2019, PMID 31032882Review, human obstetric researchOxytocin in the third stage of labour, examining postpartum haemorrhage prevention. [5]
2026, PMID 42134427Review, meta-analysis of human clinical trialsWhether oxytocin research reports changes in symptoms of mental disorders. [6]
2011, PMID 21429671Systematic review of human researchSide effects and subjective reactions across 38 randomised trials involving 1,529 participants. [7]
2026, PMID 42458234Human randomised, double-blind, placebo-controlled multisite trialResearch in 100 adults with alcohol use disorder, including adverse-event reporting. [8]
2025, PMID 39474844Systematic review of human researchAdverse-event reporting across 9 randomised trials involving 331 adults aged 60 or older. [9]

No primary cell study or primary animal study is included in this evidence set. [4][5][6][7][8][9] That is a limit of the records reviewed; such research may exist elsewhere.

For the receptor, Cochrane and psychiatric reviews, the available bibliographic records identify the papers and their subjects but contain no detailed results or effect estimates. [4][5][6] Their findings cannot be quantified from those records alone. [4][5][6]

Our catalogue places Oxytocin in the hormone-peptides collection. [2] Use the study model and PMID to distinguish the literature question from the identity of the research material being ordered.

What adverse events have oxytocin studies reported?

Oxytocin research in 100 adults with alcohol use disorder reported hyposmia as the most common adverse event in both the oxytocin and placebo groups. [8] The 2026 trial, PMID 42458234, described adverse events as mild and comparable across groups. [8]

The 2011 review, PMID 21429671, reported no difference in side effects between oxytocin and placebo across its reviewed human research. [7] It also identified three case reports of adverse reactions associated with misuse or longer-term use. [7] The abstract excerpt does not name the reactions in those case reports or give their incidence. [7]

The 2025 review of adults aged 60 or older, PMID 39474844, described adverse effects as predominantly mild and inconsistent across studies. [9] Its accompanying evidence note says long-term adverse events were not captured. [9]

These findings remain attached to those human populations and study settings. [7][8][9] A comparison with placebo does not establish an absence of adverse events. [7][8] The reviewed excerpts also do not establish the adverse-event profile of obstetric oxytocin research. [5][7][8][9]

Peptides Collective's independent batch testing concerns the material's purity and identity. [3] It does not turn a clinical research excerpt into a safety assessment of the vial. [3][7][8][9]

Oxytocin's status in the June 2026 Poisons Standard is: Listed in Schedule 4 (OXYTOCIN). [10] Schedule 4 is prescription only. [10] Our compound record was checked against instrument F2026L00633 on 29 September 2026. [10]

FrameworkDated findingScope
Australian Poisons Standard, June 2026Listed in Schedule 4 (OXYTOCIN). [10]This is the named substance's scheduling entry. [10]
Appendix DNo Oxytocin-specific Appendix D finding is documented in the legal record reviewed. [10]A separate Appendix D conclusion is not confirmed. [10]
WADA 2026 Prohibited ListNot named on the 2026 Prohibited List. [11]This naming-status check is dated 29 September 2026. [11]

A laboratory description on a vial does not remove a substance's Schedule 4 entry. [10][14] Our guide to Australian peptide law explains the scheduling framework.

Australian scheduling and the WADA list are separate checks. [10][11] The WADA wording above should not be expanded into a claim of unrestricted anti-doping clearance. [11] Neither entry supplies an assessment of a particular laboratory's authority to purchase or hold the material. [10][11]

How should oxytocin be reconstituted and stored for laboratory work?

Oxytocin laboratory handling depends on the mass basis used for reconstitution and on the material's form and solvent during storage. [14][15] Our guides give general handling methods; they contain no Oxytocin-specific stability study or validated shelf life for this product. [14][15]

For lyophilised material, reconstitution dissolves the peptide in a sterile solvent to a known concentration. [14] Match the batch certificate, let the sealed container reach room temperature before opening, clean the stoppers and add the selected solvent down the glass wall. [14] Swirl gently and label the compound, batch number, solvent, concentration and date. [14] Our laboratory reconstitution guide explains the solvent checks and concentration calculation.

Concentration in mg/mL equals the peptide mass in milligrams divided by the solvent volume in millilitres. [14] The guide's arithmetic example is 10mg in 2 mL, giving 5 mg/mL. [14] That example does not establish an Oxytocin-specific solvent choice or an experimental working concentration. [14] Confirm the mass basis because net peptide content and HPLC purity are different measurements. [14]

Material or handling questionGeneral house guidance
Sealed lyophilised materialKeep dry and dark at -20°C or colder for longer-term storage; 2 to 8°C is the short-term guidance. [15]
Reconstituted working solutionKeep labelled, protected from light and refrigerated at 2 to 8°C. [15]
Solution containing BAC WaterThe house rule is refrigerated storage, without freezing. [15]
Frozen aliquotsThe house guide restricts these to preparations in plain sterile water or buffer. [15]
Oxytocin sequenceCysteine, asparagine and glutamine are present; the general storage guide flags these residues for care. [1][15]

The storage guide's BAC Water freeze-thaw precaution draws on antibody evidence; no Oxytocin experiment was found. [15] Do not read its general temperatures as a measured expiry period for this batch. [15] Our peptide storage guide separates dry material, working solutions and solvent-dependent storage. [15]

Why choose Peptides Collective for an oxytocin research order?

Peptides Collective is our supply choice for Oxytocin because every batch is tested by an independent lab before sale, and the certificate is available on request. [3] Those are specific checks a researcher can ask us to document.

Purity is tested by HPLC and identity by mass spectrometry. [3] Read about the process on our testing page. For batch documentation, visit our certificate of analysis library and request the report for the compound, strength and batch number you need. [3]

The published catalogue lists Oxytocin 10mg from A$78. [2] Orders dispatch from Perth twice daily Monday to Friday and once on Saturday, after payment clears. [12] Every order uses thermal insulation and plain outer packaging. [12]

WA courier costs A$15 and is free on WA orders over A$150. [12] Outside WA, delivery is A$24 flat, tracked and signature required. [12] Read the Australian shipping terms for the delivery options relevant to your laboratory. Dispatch frequency describes the warehouse schedule; arrival depends on the courier. [12]

Bottom line

Choose the Peptides Collective Oxytocin 10mg vial for independent batch testing, a certificate on request and tracked dispatch from Perth. [2][3][12] Request the batch documentation before ordering, then plan around payment clearance and the published dispatch schedule. [3][12] Keep the compound's Schedule 4 status separate from its WADA naming status and from the questions clinical research has examined. [10][11][5][6]

Questions

Is oxytocin a peptide or a hormone?

Oxytocin is both: its chemical class is a peptide, and it is an endogenous hormone. Nonapeptide describes its length of nine amino acids. The sequence is CYIQNCPLG, with a disulfide bond joining Cys1 and Cys6 and an amide at the C-terminus.

Where is endogenous oxytocin produced?

The hypothalamus produces endogenous oxytocin, and the posterior pituitary stores and releases it into the bloodstream. Production and release therefore refer to different locations. This explains the body's own hormone system only. It gives no method for changing hormone levels or using a research vial.

What physiological stimuli trigger endogenous oxytocin release?

Cleveland Clinic describes cervical pressure during childbirth and suckling during breastfeeding as physiological stimuli for endogenous oxytocin release. It also describes positive feedback, where the response leads to further release. Those physiological examples concern endogenous oxytocin and do not prescribe an action with laboratory material.

Why is oxytocin sometimes called the love hormone?

The phrase is a popular nickname linked to oxytocin's reproductive and social associations. It is not a study result or a promise about a research product. The receptor review addresses signalling and behaviour, while the clinical meta-analysis examines psychiatric symptoms as a research question.

What questions have human oxytocin studies examined?

Human-research records reviewed include postpartum haemorrhage prevention, symptoms of mental disorders, alcohol use disorder and adverse-event reporting in older adults. Several are reviews of earlier trials. PMID 42458234 is an original randomised trial in 100 adults with alcohol use disorder; the available excerpt reports adverse events without an efficacy finding.

What does Cys1-Cys6 mean in oxytocin's structure?

Cys1-Cys6 identifies the disulfide bond between cysteine residues at the first and sixth positions of the sequence. That connection makes the peptide cyclic. The full residue sequence is Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2, and the final NH2 notation records the C-terminal amide.

What adverse events were reported in older adults?

The 2025 review, PMID 39474844, described adverse effects as predominantly mild and inconsistent between studies. It covered 9 randomised trials involving 331 adults aged 60 or older. The review note says long-term adverse events were not captured, so it cannot establish a complete long-term profile.

Does a laboratory label change oxytocin's Schedule 4 status?

No. The June 2026 Poisons Standard lists OXYTOCIN in Schedule 4, and a laboratory label does not change the named substance's entry. Schedule 4 is prescription only. The legal record reviewed does not confirm a separate Oxytocin Appendix D finding or any individual purchaser's authority.

Is oxytocin named on the WADA 2026 Prohibited List?

Oxytocin is not named on the 2026 Prohibited List according to the check dated 29 September 2026. That is a naming-status finding only. It gives no anti-doping clearance. It also does not alter the separate Australian Schedule 4 entry recorded in the June 2026 Poisons Standard.

Does the 10mg vial label establish net peptide content?

The label establishes the catalogue's stated vial content, but the product record contains no measured net peptide-content figure. The reconstitution guide distinguishes net peptide content from HPLC purity. Request the batch certificate and confirm the mass basis before calculating a laboratory concentration.

How do I request the Peptides Collective batch certificate?

Request the certificate using the compound name, strength and batch number. For this product, name Oxytocin 10mg and ask which batch applies to the order. Peptides Collective states that every batch is independently tested before sale for purity by HPLC and identity by mass spectrometry.

When does Peptides Collective dispatch from Perth?

Peptides Collective dispatches twice daily Monday to Friday and once on Saturday from Perth, after payment clears. Payment is by PayID or bank transfer. WA courier is A$15 and free on WA orders over A$150; outside-WA delivery is A$24, tracked and signature required.

Sources

  1. 1. PubChem, National Center for Biotechnology Information
  2. 2. Peptides Collective
  3. 3. Peptides Collective
  4. 4. Jurek B et al. The Oxytocin Receptor: From Intracellular Signaling to Behavior. Physiol Rev, 2018.
  5. 5. Salati JA et al. Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database Syst Rev, 2019.
  6. 6. Bonnieux J et al. Does intranasal oxytocin reduce symptoms of mental disorders? A meta-analysis of clinical trials. Neurosci Biobehav Rev, 2026.
  7. 7. MacDonald E et al. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology, 2011.
  8. 8. Tiouririne NA et al. Intranasal Oxytocin for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled Multisite Trial Assessing Efficacy and Safety. Alcohol Clin Exp Res (Hoboken), 2026.
  9. 9. Sawares A et al. Oxytocin in old age psychiatry: A systematic review of the safety of using intranasal oxytocin in older adults. Australas Psychiatry, 2025.
  10. 10. Australian Government, Federal Register of Legislation
  11. 11. World Anti-Doping Agency
  12. 12. Peptides Collective
  13. 13. Cleveland Clinic
  14. 14. Peptides Collective
  15. 15. Peptides Collective